Effect of Thal and IMiDs on T cells in healthy donors and patients with MM.

(A) CD3⁺ cells from 4 healthy donors (left) and 4 patients with MM (right) were stimulated with anti-CD3 and treated with Thal/IMiDs daily for 5 days. Values represent the stimulation index (± SD) in the presence of Thal/IMiDs (0.1, 1, and 5 μg/mL). (B) IFN-γ and IL-2 levels were measured using enzyme-linked immunosorbent assay in supernatants of anti-CD3–stimulated CD3⁺ cells cultured with Thal or IMiDs (5 μg/mL) for 5 days. (C) CD3⁺ (♦), CD4⁺ (▪), and CD8⁺ (▴) cells were selected using immunomagnetic beads. Cells were stimulated with anti-CD3 and treated with Thal (left panel) and IMiD2 (right panel) daily for 5 days. Proliferation was assayed as described above in the presence of Thal/IMiD2 (0.1, 1, and 5 μg/mL).